Mesalamine-related lung disease: Clinical, radiographic, and pathologic manifestations

Inflammatory Bowel Diseases

Volumn 9, Issue 5, 2003, Pages 308-315

  Foster, Runi A ^a   Zander, Dani S ^a,b   Mergo, Patricia J ^a   Valentine, John F ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug induced; Hypersensitivity pneumonia; Inflammatory bowel diseases; Interstitial pneumonia; Mesalamine

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; BRONCHITIS; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CROHN DISEASE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXEMIA; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG LAVAGE; LUNG VOLUME; MALE; NIGHT SWEAT; OPEN LUNG BIOPSY; PATHOLOGY; PHYSICAL EXAMINATION; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TACHYPNEA; THORAX PAIN; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TRANSBRONCHIAL BIOPSY; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MESALAMINE;

EID: 0141854032     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200309000-00004     Document Type: Review

References (38)

1. Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990;112:50-60.
2. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes. Gastroenterology 1999;116:602-9.
3. Valentine JF. Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. Am J Physiol Gastrointest Liver Physiol 2001;281:G1044-50.
4. Watkinson G. Sulphasalazine: a review of 40 years' experience. Drugs 1986;32(suppl1):1-11.
5. Hamadeh M, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992;101:1033-7.
6. Jones GR, Malone DN. Sulfasalazine induced lung disease. Thorax 1972;27:713-7.
7. Honeybourne D. Mesalazine toxicity. Br Med J 1994;308:553-4.
8. Muzzi A, Ciani F, Bianchini D, et al. Adverse pulmonary effects of mesalamine. Chest 1995;108:1181.
9. Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest 1992;101:1469-71.
10. Welte T, Hamm H, Gabel H. Mesalazine alveolitis. Lancet 1991; 338:1273.
11. Sviri S, Gafanovich I, Kramer MR, et al. Mesalamine-induced hypersensitivity pneumonitis. J Clin Gastroenterol 1994;24:34-6.
12. Limper AH, Rosenow EC. Drug induced pulmonary disease. In: Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. Philadelphia: WB Saunders, 2000:1971-94.
13. Kuzela L, Vavrecka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999;46:1714-9.
14. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal manifestations of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
15. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine 1993;72:151-80.
16. Baillie J. Sulfasalazine and pulmonary infiltrates. Am J Gastroenterol 1984;79:77.
17. Averbuch M, Halpern Z, Hallak A, et al. Sulfasalazine pneumonitis. Am J Gastroenterol 1985;80:343.
18. Brimblecombe R. Mesalamine: a global safety evaluation. Scand J Gastroenterol Suppl 1990;172:66.
19. Tanigawa K, Sugiyami K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999;66:69-72.
20. Bitton A, Peppercorn MA, Hanrahan JP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996;91:1039.
21. Lazaro MT, Garcia-Tejero MT, Diaz-Lobato S. Mesalamine-induced lung disease. Arch Intern Med 1997;157:462.
22. Saltzman K, Rossoff LJ, Gouda H, et al. Mesalamine-induced unilateral eosinophilic pneumonia. AJR 2001;177:257.
23. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease: noncytotoxic drugs. Am J Respir Crit Care Med 1986; 133:488.
24. Sesin GP, Mucciardi N, Almeida S. Mesalamine-associated pleural effusion with pulmonary infiltration. Am J Health Syst Pharm 1998;55:2304-5.
25. Reyes CN, Wenzel FJ, Lawton BR, et al. The pulmonary pathology of farmer's lung disease. Chest 1982;81:142-6.
26. Burke GW, Carrington CB, Strauss R, et al. Allergic alveolitis caused by home humidifiers: unusual clinical features and electron microscopic findings. JAMA 1977;238:2705-8.
27. Kawanami O, Basset F, Barrios R, et al. Hypersensitivity pneumonitis in man. Am J Pathol 1983;110:275-89.
28. Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995;107:1763-5.
29. Sostman HD, Matthay RA, Putman CE, et al. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976;55:371-88.
30. Manicardi V, Bernini G, Bossini P, et al. Low-dose amiodarone-induced pneumonitis: evidence of an immunologic pathogenetic mechanism. Am J Med 1989;86:134-5.
31. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987;18:349-54.
32. Nilubol N, Taub PJ, Venturero M, et al. Ulcerative colitis and sarcoidosis. Mt Sinai J Med 2001;68:400-2.
33. Cox NH, McCrea JD. A case of Sjogren's syndrome, sarcoidosis, previous ulcerative colitis and gastric autoantibodies. Br J Dermatol 1996;134:1138-10.
34. Fries W, Grassi SA, Leone L, et al. Association between inflammatory bowel disease and sarcoidosis: report of two cases and review of the literature. Scand J Gastroenterol 1995;30:1221-3.
35. Johnson CD. Obstructive jaundice in a patient with ulcerative colitis, Sjogren's syndrome and sarcoidosis. J R Soc Med 1989;82: 362.
36. Barr GD, Shale DJ, Jewell DP. Ulcerative colitis and sarcoidosis. Postgrad Med J 1986;62:341-5.
37. Theodoropoulos G, Archimandritis A, Davaris P, et al. Ulcerative colitis and sarcoidosis: a curious association-report of a case. Dis Colon Rectum 1981;24:308-10.
38. Le Gros V, Saveuse H, Lesur G. Lung and skin hypersensitivity to 5-aminosalicylic acid. Br Med J 1991;1:970.